DAXOR CORPORATION - CLOSED END FUND

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

23 3 2023 08:30:00 提供 Nasdaq GlobeNewswire

Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients

23 3 2023 08:00:01 提供 Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

03 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

02 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update

01 3 2023 08:00:02 提供 Nasdaq GlobeNewswire

Daxor Corporation Appoints Linda Cooper, Vice President Project Management

17 2 2023 08:00:00 提供 Nasdaq GlobeNewswire

Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member

19 1 2023 08:00:01 提供 Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress

13 1 2023 08:00:00 提供 Nasdaq GlobeNewswire

Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

03 1 2023 08:00:01 提供 Nasdaq GlobeNewswire

Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option

17 11 2022 11:07:00 提供 Nasdaq GlobeNewswire

Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering

15 11 2022 08:45:00 提供 Nasdaq GlobeNewswire

Daxor Corporation Announces Launch of Proposed Underwritten Public Offering

14 11 2022 17:03:51 提供 Nasdaq GlobeNewswire

Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs

10 11 2022 08:00:02 提供 Nasdaq GlobeNewswire

Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

03 11 2022 08:00:01 提供 Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022

31 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting

05 10 2022 08:30:00 提供 Nasdaq GlobeNewswire

DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)

04 10 2022 08:30:00 提供 Nasdaq GlobeNewswire

Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting

04 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%

03 10 2022 09:00:01 提供 Nasdaq GlobeNewswire

New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care

03 10 2022 08:40:00 提供 Nasdaq GlobeNewswire